Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B
Alimentary Pharmacology and Therapeutics, Volume 29, No. 4, Year 2009
Notification
URL copied to clipboard!
Description
Background: The Fib-4 index is a simple and inexpensive biomarker to delineate liver fibrosis in chronic hepatitis C. Aim: To assess the accuracy of the FIB-4 index in chronic hepatitis B. Methods: We compared the FIB-4 index with 138 synchronous liver biopsies and with 372 synchronous FibroTest performed either in France or in an endemic area (Mayotte, an overseas collectivity of France). Results: The FIB-4 index allowed the correct identification of patients with nil-to-moderate fibrosis with an area under the receiving operating characteristic curve of 0.81 (P < 0.001), increasing as a function of the length of the liver biopsy (up to 0.94 for liver biopsies ≥20 mm). A cut-off value ≤1.45 differentiated moderate fibrosis from severe fibrosis with a negative predictive value of 86%, a sensitivity of 71.1% and a specificity of 73.1%. Beyond 1.45, the FIB-4 index was not informative. The FIB-4 index was more precise than the AST-to-platelet ratio index and correlated with the FibroTest in 89% of the cases (κ = 0.27, P < 0.001) to exclude severe fibrosis. Conclusion: The FIB-4 index is a simple, accurate and inexpensive method to exclude significant liver fibrosis in chronic hepatitis B, a major advantage in HBV-endemic developing countries. © 2009 The Authors.
Authors & Co-Authors
Mallet, V. Olivier
France, Paris
Université Paris Cité
France, Paris
Hopital Cochin Ap-hp
France, Paris
Inserm
Dhalluin-Venier, V.
France, Paris
Université Paris Cité
France, Paris
Hopital Cochin Ap-hp
Roussin, Céline
Mayotte, Mamoudzou
Centre Hospitalier de Mayotte
Bourlier̀e, Marc
France, Marseille
Hôpital Saint Joseph
Pettinelli, M. E.
Mayotte, Mamoudzou
Centre Hospitalier de Mayotte
Giry, Claude
Mayotte, Mamoudzou
Centre Hospitalier de Mayotte
Vallet-Pichard, A.
France, Paris
Université Paris Cité
France, Paris
Hopital Cochin Ap-hp
France, Paris
Inserm
Fontaine, H.
France, Paris
Hopital Cochin Ap-hp
France, Paris
Inserm
Pol, Stanislas
France, Paris
Université Paris Cité
France, Paris
Hopital Cochin Ap-hp
France, Paris
Inserm
Statistics
Citations: 108
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1111/j.1365-2036.2008.03895.x
ISSN:
02692813
e-ISSN:
13652036
Research Areas
Infectious Diseases